0000000000810420

AUTHOR

Fiore Manganelli

showing 6 related works from this author

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

2022

Background: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. Methods: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. Results: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96.3%) were fully vaccinated. Adherence to vaccination was higher in patients with hereditary neuropathies compared to others, while it was lower in …

General NeuroscienceSARS-CoV-2 infectionCIDP COVID-19 vaccines SARS-CoV-2 infection autoimmune neuropathy hereditary neuropathy neuropathy reactogenicity vaccine hesitancy vaccine safetyreactogenicityvaccine hesitancySARS-CoV-2 infection; COVID-19 vaccines; reactogenicity; vaccine safety; vaccine hesitancy; neuropathy; autoimmune neuropathy; hereditary neuropathy; CIDPneuropathyvaccine safetyCIDPhereditary neuropathyCOVID-19 vaccineautoimmune neuropathy
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct

Machine Learning for Early Diagnosis of ATTRv Amyloidosis in Non-Endemic Areas: A Multicenter Study from Italy

2023

Background: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv) is an adult-onset multisystemic disease, affecting the peripheral nerves, heart, gastrointestinal tract, eyes, and kidneys. Nowadays, several treatment options are available; thus, avoiding misdiagnosis is crucial to starting therapy in early disease stages. However, clinical diagnosis may be difficult, as the disease may present with unspecific symptoms and signs. We hypothesize that the diagnostic process may benefit from the use of machine learning (ML). Methods: 397 patients referring to neuromuscular clinics in 4 centers from the south of Italy with neuropathy and at least 1 more red flag, as well as undergoin…

machine learningATTRvGeneral Neurosciencegenetic screeninghereditary amyloid neuropathyTTRTTR; hereditary amyloid neuropathy; genetic screening; ATTRv; machine learning; genetic testinggenetic testingBrain Sciences
researchProduct

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

2016

Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects h…

MaleTafamidisAmyloid polyneuropathyNeurologyCardiomyopathyDisease030204 cardiovascular system & hematologySeverity of Illness IndexTransthyretinchemistry.chemical_compound0302 clinical medicinePrealbuminTafamidiLongitudinal StudiesStage (cooking)Aged 80 and overBenzoxazolesbiologyAmyloidosisMiddle Agedamyloid polyneuropathy; tafamidis; transthyretinPrognosisTafamidisSettore MED/26 - NEUROLOGIATreatment OutcomeItalyNeurologyDisease ProgressionFemaleAmyloid polyneuropathy; Tafamidis; Transthyretin; Neurology (clinical); NeurologyAdultmedicine.medical_specialty03 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansAgedAmyloid Neuropathies Familialbusiness.industrynutritional and metabolic diseasesmedicine.diseaseSurgeryTransthyretinchemistryMutationbiology.proteinNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurology
researchProduct

Dataset related to article "Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiag…

2021

This record contains data related to article “Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?" Abstract Background and purpose: The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. Methods: The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed. Results: In all, 535 p…

chronic inflammatory demyelinating polyradiculoneuropathydiagnostic criteriaelectrophysiology
researchProduct

Dataset relative to article "Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy"

2021

This record contains data related to article “Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy". Abstract For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There…

chronic inflammatory demyelinating polyradiculoneuropathySensitivitynervous systemAnti-MAG polyneuropathyELISASpecificity.
researchProduct